Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-659 and Paclitaxel in Advanced Solid Tumors
NCT03756818Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2019
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mivavotinib in solid tumor (advanced stage) and ovarian carcinoma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose up to 4 years. Started Mar 2019; status: completed.
02
Drugs
mivavotinib
03
Conditions
solid tumor (advanced stage)ovarian carcinoma
Beyond the preview
Go deeper on NCT03756818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03756818.